NEUMORA THERAPEUTICS INC (NMRA)
US6409791000 - Common Stock
Noteworthy Friday Option Activity: NMRA, WMT, CMRE
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of...
Neumora Therapeutics to Participate in Upcoming Conferences in November
Neumora Therapeutics to Participate in Upcoming Conferences in November
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a...
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a...
Notable Wednesday Option Activity: GM, NMRA, FULC
Commit To Purchase Neumora Therapeutics At $10, Earn 66.1% Annualized Using Options
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET
Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders
Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET...
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Neumora Therapeutics (NASDAQ:NMRA) just reported results for the second quarter...
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and...
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of...
Neumora Therapeutics Enters Oversold Territory (NMRA)
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve...
NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024
NMRA stock results show that Neumora Therapeutics met analyst estimates for earnings per share the first quarter of 2024.
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study...
Neumora Therapeutics to Participate in Upcoming Conferences in May
Neumora Therapeutics Becomes Oversold (NMRA)
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Why Is Mobile Global Esports (MGAM) Stock Down 18% Today?
Mobile Global Esports stock is falling on Monday after the company revealed that shares of MGAM will be delisted later this week.
Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today?
Neumora Therapeutics stock is falling on Monday as investors in NMRA shares react to a clinical trial being put on hold by the FDA.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning!
Neumora Tumbles as Early-Stage Study Put on Clinical Hold
Neumora Therapeutics Inc. fell in premarket trading after US regulators put a clinical hold on an early-stage study of its brain disease treatment following new data linking the therapy to convulsions in rabbits.
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a...